Montrouge,
The data to be presented include new long-term results of the Phase 3 REALISE (REAL Life Use and Safety of EPIT™) study in children 4-11 years of age, including the safety of Viaskin Peanut over three years and potential impact on health-related quality of life (HRQL).
“These data presented at ACAAI contribute to our understanding of and excitement for the potential real-world use of Viaskin Peanut, if approved.” said Dr.
DBV is also sponsoring the 30th Annual FIT Bowl, a game show-type competition that tests the knowledge of participating teams from training programs around the country.
Viaskin Peanut is the Company’s lead product candidate designed to reduce the risk of allergic reactions due to accidental exposure to peanuts. An investigational non-invasive, once daily, epicutaneous patch, Viaskin Peanut seeks to deliver microgram quantities of peanut antigen to re-educate the immune system. Viaskin Peanut is DBV’s proprietary approach to epicutaneous immunotherapy (EPIT), a method of delivering biologically active compounds to the immune system through the skin.
DBV Abstracts:
Oral Presentation
“REALISE (Real-life Use and Safety of EPIT) Study: 3 Year Results in Peanut-Allergic Children” will be presented by
- Session Code: D030
- Session Title: Distinguished Industry Oral Abstracts – Session B
- Presentation Date:
Saturday, November 6, 2021 - Presentation Time:
4:33-4:43 pm CT
Poster Presentation
“REALISE (Real-life Use and Safety of EPIT) Study: Health-related Quality of Life Changes During Treatment” will be presented by
- Abstract Number: P116
- Presentation Date:
Saturday, November 6, 2021 - Presentation Time:
12:35 pm CT - Presentation Location: Monitor 11 in the ePoster Area of the Exhibit Hall
About
Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of Viaskin™ Peanut as a treatment for peanut-allergic children and the potential benefits of EPIT. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, including the impact of the COVID-19 pandemic, and DBV’s ability to successfully execute on its restructuring plans. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the
Investor Contact
+1 857-529-2363
anne.pollak@dbv-technologies.com
Media Contact
+1 646-842-2393
angela.marcucci@dbv-technologies.com
Attachment
- PDF Version
Source:
2021 GlobeNewswire, Inc., source